Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL6717257 | 0.91 | CDK1 (0.65) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL460227 | 0.88 | CDK1 (0.56) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL875991 | 0.87 | CDK1 (0.66) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL8619982 | 0.84 | CDK1 (0.57) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL9300815 | 0.83 | CDK1 (0.60) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL323058 | 0.82 | CDK1 (0.63) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL55938 | 0.82 | CDK1 (0.57) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL20511784 | 0.82 | CDK1 (0.57) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL1548134 | 0.81 | CDK1 (0.54) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL8854190 | 0.81 | CDK1 (0.56) | CDK1CCNB1CA2CA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040210047-A1 | Methallyl sucroses and their epoxy derivatives | SACHINVALA NAVZER D (US) | 2004-10-21 | — | — | US | claimed |
| US-20040210047-A1 | Methallyl sucroses and their epoxy derivatives | SACHINVALA NAVZER D (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210047-A1 | Methallyl sucroses and their epoxy derivatives | SORD, SELE, GALE | CDK1 4261/4885CCNB1 4255/4885CA2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.